You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser.
Administrator
Staff member
-
cafead   Jul 05, 2023 at 07:22: PM
Administrator
Staff member
via Another FDA accelerated approval has run its course, with Roche giving up on a niche indication for cancer drug Gavreto.
article source